Avedro is formerly owned by Abingworth, through Abingworth Bioventures VI, since 2014.

When did Abingworth acquire Avedro?

Abingworth acquired Avedro in 2014 and exited after 5 years.

Has Avedro been sold?

Yes. Avedro was exited in 2019 via Trade Sale.

Home/Companies/MedTech/Avedro

Avedro

MedTech·

US·Exited 2019·Held 5yr

Avedro is a MedTech company, headquartered in US.

Entry

2014

Hold

5yr

Exit

2019

Est. EV

–

Investor

Abingworth

Key facts

HQUS

SectorMedTech

StatusAcquired

US ophthalmic medical-technology company focused on corneal cross-linking therapies for keratoconus, acquired by Glaukos in 2019.

See the full ownership history.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Full fund context: vintage, strategy, region

Exit details: type, year, MOIC (buyer on Pro)

Start free

Already a member? Sign in

More from Abingworth Bioventures VI

Other portfolio companies in the same fund.

eFFECTOR Therapeutics

Exited 2021

Biotech

US· 2013

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Villard

Active

Yotta Capital Partners

France· 2026

Amoena

Active

Apera Asset Management

Last updated May 2026 · Sourced from public filings